$95.8 Million is the total value of M28 Capital Management LP's 12 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | INVIVYD INC | $28,947,000 | +37.9% | 9,248,250 | +44.5% | 30.22% | +28.4% | |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $5,102,000 | +20.5% | 513,300 | +10.1% | 5.33% | +12.2% |
| CRIS | Buy | CURIS INC | $3,137,000 | -24.9% | 4,482,142 | +5.6% | 3.28% | -30.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-10
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 46.4% |
| INVIVYD INC | 8 | Q3 2023 | 32.1% |
| ROCKET PHARMACEUTICALS INC | 8 | Q3 2023 | 16.6% |
| BRIDGEBIO PHARMA INC | 8 | Q3 2023 | 6.1% |
| TG THERAPEUTICS INC | 8 | Q3 2023 | 9.2% |
| NEXIMMUNE INC | 8 | Q3 2023 | 0.5% |
| STOKE THERAPEUTICS INC | 7 | Q2 2023 | 10.2% |
| CURIS INC | 7 | Q2 2023 | 9.7% |
| PROQR THRAPEUTICS N V | 7 | Q3 2023 | 6.7% |
| ATARA BIOTHERAPEUTICS INC | 5 | Q1 2023 | 5.6% |
View M28 Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adagio Therapeutics, Inc. | August 19, 2022 | 9,248,250 | 8.5% |
View M28 Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-12 |
| SC 13G/A | 2024-02-12 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-05-25 |
| 13F-HR | 2023-05-12 |
View M28 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.